Loading…
← CockpitCompetitor Analysis › 600488.SS Tianjin Tianyao Pharmaceuticals Co., Ltd. Class AOpen in the cockpit ↗

Tianjin Tianyao Pharmaceuticals Co., Ltd. Class A600488.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Other
Momentum weak 20
Mkt cap
$718M
US dollars, full cap
Free float
42%
of shares outstanding
$/day
$29.1M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-0.1 pp
WACC 5.0%
Hurdle
+3 pp
Req g minus delivered
Close · CNYCN¥4.47
1D-0.9%
1W-10.1%
1M-18.1%
3M-24.9%
6M-36.2%
YTD+9.3%
1Y+3.5%
ATR %4.9%
52w lowhigh47.0% off high

What Tianjin Tianyao Pharmaceuticals does

Employees: 2,731

Tianjin Tianyao Pharmaceuticals at a glance

Size Tianjin Tianyao Pharmaceuticals (600488.SS) is a China Health Care company (Pharmaceuticals: Other) with a market value of $718M, the 2843rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥4.47 on 18 Nov 2026.

Performance Over six months the shares fell 36.2%, against -19.1% for the median peer and -20.0% for the China market (cap-weighted) — 3rd lowest of 21 in its peer set.

Growth Revenue fell 11.6% over the last twelve months (peer median -2.6%); the operating margin is 3.3% (peer median 9.5%).

Valuation It trades at 2.2× enterprise value to sales against a peer median of 3.0× (8th cheapest of 20).

Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.1 points below its cost of capital (5.0% WACC).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 81600488.SS 71
Six months, rebased to 100: Tianjin Tianyao Pharmaceuticals against the median of its 20 peers (local-currency closes).

Tianjin Tianyao Pharmaceuticals financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.54BCN¥2.89BCN¥3.19BCN¥3.75BCN¥3.66B
Revenue growth—-10%-15%+2%—
Gross profitCN¥1.15BCN¥1.09BCN¥1.36BCN¥1.65BCN¥1.71B
EBITDAn/aCN¥536MCN¥556MCN¥434MCN¥438M
Net incomeCN¥46.7MCN¥70.6MCN¥133MCN¥117MCN¥35.4M
Free cash flowCN¥361MCN¥82.3MCN¥492MCN¥650MCN¥446M
Capital expenditureCN¥41.7MCN¥55.9MCN¥77.7MCN¥133MCN¥202M
Total debtCN¥800MCN¥826MCN¥644MCN¥995MCN¥1.58B

Quarterly statements and history in the cockpit →

Tianjin Tianyao Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%-20%0%300039300791287700256230015807756032620460300261301507AVBPPHN002644002219002412APN000756002275603669317450600488.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Tianjin Tianyao Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%2.5×5×7.5×30003930079100256230015807756032620460300261301507PHN002644002219002412APN000756603669317450600488.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Tianjin Tianyao Pharmaceuticals is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%300039300791002562603262301507PHN002644002412APN002275600488.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Tianjin Tianyao Pharmaceuticals is the large dot.

Tianjin Tianyao Pharmaceuticals competitors and peer comparison

How Tianjin Tianyao Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Tianjin Tianyao Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
Measure600488.SSPeer medianRank in peer set
1-month return-18.1%-9.3%3rd lowest of 21
6-month return-36.2%-19.1%3rd lowest of 21
Distance from 52-week high-47.0%-41.8%9th lowest of 21
Revenue growth (TTM)-11.6%-2.6%6th lowest of 20
Operating margin3.3%9.5%7th lowest of 21
EV / Sales2.2×3.0×8th cheapest of 20
Growth the price implies (Req g, 7 yrs)2.1%4.7%5th least demanding of 12
Growth delivered (Del g)-1.3%+12.1%lowest of 12
Hurdle (Req g minus delivered)+3.4 pp-5.5 pp4th most demanding of 12
ROIC minus cost of capital-0.1 pp+0.4 pp10th lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Tianjin Tianyao Pharmaceuticals 600488.SSChina$718M-36%-12%3%2.2×2.1%-1.3%
Shanghai Kaibao Pharmaceutical 300039.SZChina$703M-20%-14%22%3.4×0.4%+4.8%
Sirio Pharma 300791.SZChina$759M-6%-9%1%1.5×14.1%+15.6%
China Shineway Pharmaceutical 2877.HKHong Kong$760M-8%-18%25%n/an/an/a
Brother Enterprises 002562.SZChina$668M-33%+8%4%1.5×4.0%+13.5%
Shanxi Zhendong Pharmaceutical 300158.SZChina$641M-22%-28%-25%1.8×n/an/a
CK Life Sciences International (Holdings) 0775.HKHong Kong$613M-30%0%0%2.0×n/an/a
TSI 603262.SSChina$842M-46%+3%14%4.6×24.3%+13.4%
Sihuan Pharmaceutical 0460.HKHong Kong$856M-34%+30%15%2.1×n/an/a
ABA Chemicals 300261.SZChina$592M-26%-16%-23%4.9×n/an/a
Hangzhou Minsheng Healthcare 301507.SZChina$583M-23%+21%11%3.8×19.1%+12.1%
ArriVent BioPharma AVBPUnited States$564M-60%n/a-3,620%34.2×n/an/a
PharmaNutra PHN.MIItaly$922M+2%+17%22%5.6×4.7%+18.5%
Lanzhou Foci Pharmaceutical 002644.SZChina$548M-9%+6%6%3.3×15.4%+6.5%
New Journey Health Technology Group Co., Ltd.Class A 002219.SZChina$942M-18%-14%8%2.9×n/an/a
Hunan Hansen Pharmaceutical 002412.SZChina$532M-2%-4%21%3.0×1.4%+7.0%
Applied Nutrition APN.LUnited Kingdom$986M+31%+51%25%4.6×24.6%+38.5%
Shandong Xinhua Pharmaceutical 000756.SZChina$1.01B-17%-5%4%0.9×0.5%+7.9%
Guilin Sanjin Pharmaceutical 002275.SZChina$1.05B-12%-3%24%2.9×-8.7%+5.5%
Lionco Pharmaceutical 603669.SSChina$474M+4%-6%-17%8.4×n/an/a
Myung in Pharm 317450.KSSouth Korea$466M-20%+7%35%0.7×n/an/a

Questions

Which companies are Tianjin Tianyao Pharmaceuticals's closest peers?
The cockpit's peer set: Shanghai Kaibao Pharmaceutical (300039.SZ), Sirio Pharma (300791.SZ), China Shineway Pharmaceutical (2877.HK), Brother Enterprises (002562.SZ), Shanxi Zhendong Pharmaceutical (300158.SZ), CK Life Sciences International (Holdings) (0775.HK), TSI (603262.SS), Sihuan Pharmaceutical (0460.HK).
Is Tianjin Tianyao Pharmaceuticals expensive compared with its peers?
On ev / sales it trades at 2.2× against a peer median of 3.0×, 8th cheapest of 20 in its peer set. For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Tianjin Tianyao Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -36.2% against -19.1% for the median peer; over one year +3.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.